PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 88 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $390,949 | -27.6% | 37,700 | 0.0% | 0.00% | – |
| Q2 2023 | $539,864 | +177.0% | 37,700 | +38.1% | 0.00% | – |
| Q1 2023 | $194,922 | -22.8% | 27,300 | +21.3% | 0.00% | – |
| Q4 2022 | $252,450 | +44.3% | 22,500 | +42.4% | 0.00% | – |
| Q3 2022 | $175,000 | +42.3% | 15,800 | +8.2% | 0.00% | – |
| Q2 2022 | $123,000 | -22.6% | 14,600 | +24.8% | 0.00% | – |
| Q1 2022 | $159,000 | -37.4% | 11,700 | -9.3% | 0.00% | – |
| Q4 2021 | $254,000 | -28.0% | 12,900 | +17.3% | 0.00% | – |
| Q3 2021 | $353,000 | -15.1% | 11,000 | -10.6% | 0.00% | – |
| Q2 2021 | $416,000 | +5.6% | 12,300 | +17.1% | 0.00% | – |
| Q1 2021 | $394,000 | +4.0% | 10,500 | -7.9% | 0.00% | – |
| Q4 2020 | $379,000 | -14.6% | 11,400 | -5.8% | 0.00% | – |
| Q3 2020 | $444,000 | -3.7% | 12,100 | -13.6% | 0.00% | – |
| Q2 2020 | $461,000 | – | 14,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 4,901,358 | $41,368,000 | 8.59% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $49,183,000 | 4.64% |
| Abingworth LLP | 1,435,106 | $12,112,000 | 3.88% |
| Penn Mutual Asset Management | 86,940 | $734,000 | 0.99% |
| 683 Capital Management, LLC | 1,440,000 | $12,153,000 | 0.86% |
| Western Standard LLC | 109,055 | $920,000 | 0.70% |
| MPM BioImpact LLC | 193,326 | $1,632,000 | 0.45% |
| Newtyn Management, LLC | 255,767 | $2,159,000 | 0.41% |
| StepStone Group LP | 422,085 | $3,562,000 | 0.38% |
| Avidity Partners Management LP | 1,919,800 | $16,203,000 | 0.37% |